ABSTRACT
RNA modifications are emerging as key determinants of gene expression. However, compelling genetic demonstrations of their relevance to human disease are lacking. Here, we link ribosomal RNA 2'-O-methylation (2'-O-Me) to the etiology of dyskeratosis congenita. We identify nucleophosmin (NPM1) as an essential regulator of 2'-O-Me on rRNA by directly binding C/D box small nucleolar RNAs, thereby modulating translation. We demonstrate the importance of 2'-O-Me-regulated translation for cellular growth, differentiation and hematopoietic stem cell maintenance, and show that Npm1 inactivation in adult hematopoietic stem cells results in bone marrow failure. We identify NPM1 germline mutations in patients with dyskeratosis congenita presenting with bone marrow failure and demonstrate that they are deficient in small nucleolar RNA binding. Mice harboring a dyskeratosis congenita germline Npm1 mutation recapitulate both hematological and nonhematological features of dyskeratosis congenita. Thus, our findings indicate that impaired 2'-O-Me can be etiological to human disease.
Subject(s)
Dyskeratosis Congenita/genetics , Epigenomics/methods , Germ-Line Mutation , Nuclear Proteins/genetics , RNA Processing, Post-Transcriptional , RNA, Messenger/genetics , RNA, Ribosomal/genetics , Animals , Dyskeratosis Congenita/pathology , Gene Expression Profiling , Hematopoietic Stem Cells , Male , Methylation , Mice , Mice, Inbred C57BL , Mice, Knockout , Nuclear Proteins/chemistry , Nucleophosmin , RNA, Small Nucleolar , TranscriptomeABSTRACT
Nucleophosmin (NPM) (B23) is an essential protein in mouse development and cell growth; however, it has been assigned numerous roles in very diverse cellular processes. Here, we present a unified mechanism for NPM's role in cell growth; NPM directs the nuclear export of both 40S and 60S ribosomal subunits. NPM interacts with rRNA and large and small ribosomal subunit proteins and also colocalizes with large and small ribosomal subunit proteins in the nucleolus, nucleus, and cytoplasm. The transduction of NPM shuttling-defective mutants or the loss of Npm1 inhibited the nuclear export of both the 40S and 60S ribosomal subunits, reduced the available pool of cytoplasmic polysomes, and diminished overall protein synthesis without affecting rRNA processing or ribosome assembly. While the inhibition of NPM shuttling can block cellular proliferation, the dramatic effects on ribosome export occur prior to cell cycle inhibition. Modest increases in NPM expression amplified the export of newly synthesized rRNAs, resulting in increased rates of protein synthesis and indicating that NPM is rate limiting in this pathway. These results support the idea that NPM-regulated ribosome export is a fundamental process in cell growth.
Subject(s)
Active Transport, Cell Nucleus , Cell Proliferation , Nuclear Proteins/physiology , Ribosomes/metabolism , Animals , Cells, Cultured , Cytoplasm , Humans , Kinetics , Mice , Mice, Knockout , Molecular Chaperones , Mutation , Nuclear Proteins/genetics , Nucleophosmin , Polyribosomes , Protein Biosynthesis , RNA, Ribosomal/metabolismSubject(s)
Centromere/metabolism , Chromosome Segregation , Molecular Chaperones/metabolism , Nuclear Pore Complex Proteins/metabolism , Animals , Antigens, Neoplasm/metabolism , Centromere/ultrastructure , DNA Topoisomerases, Type II/metabolism , DNA-Binding Proteins/metabolism , Fibroblasts/cytology , Fibroblasts/physiology , Genomic Instability , Humans , Mice , Molecular Chaperones/genetics , Nuclear Pore Complex Proteins/geneticsABSTRACT
Nucleophosmin (NPM1) gene has been heavily implicated in cancer pathogenesis both as a putative proto-oncogene and tumor suppressor gene. NPM1 is the most frequently mutated gene in acute myeloid leukemia (AML), while deletion of 5q, where NPM1 maps, is frequent in patients with myelodysplastic syndromes (MDS). We have previously shown that mice heterozygous for Npm1 (Npm1+/-) develop a hematologic syndrome with features of human MDS. Here we analyzed Npm1+/- mutants to determine their susceptibility to cancer. Npm1+/- mice displayed a greater propensity to develop malignancies compared with Npm1+/+ mice. The Npm1+/- cohort frequently developed hematologic malignancies of both myeloid and lymphoid origin with myeloid malignancies displaying the highest incidence. Malignant cells retained the wild-type allele with normal localization and expression of Npm1 at the protein level, suggesting that complete Npm1 loss is not a prerequisite for tumorigenesis. Our results conclusively demonstrate that Npm1 acts as a haploinsufficient tumor suppressor in the hematopoietic compartment.
Subject(s)
Cell Transformation, Neoplastic/metabolism , Hematologic Neoplasms/metabolism , Nuclear Proteins/metabolism , Oncogene Proteins/metabolism , Tumor Suppressor Proteins/metabolism , Alleles , Animals , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Hematologic Neoplasms/genetics , Humans , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/metabolism , Leukemia, Myeloid, Acute/pathology , Mice , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/metabolism , Myelodysplastic Syndromes/pathology , Nuclear Proteins/genetics , Nucleophosmin , Oncogene Proteins/genetics , Proto-Oncogene Mas , Tumor Suppressor Proteins/geneticsABSTRACT
Loss of the promyelocytic leukaemia (PML) tumour suppressor has been observed in several human cancers. The tumour-suppressive function of PML has been attributed to its ability to induce growth arrest, cellular senescence and apoptosis. Here we identify PML as a critical inhibitor of neoangiogenesis (the formation of new blood vessels) in vivo, in both ischaemic and neoplastic conditions, through the control of protein translation. We demonstrate that in hypoxic conditions PML acts as a negative regulator of the synthesis rate of hypoxia-inducible factor 1alpha (HIF-1alpha) by repressing mammalian target of rapamycin (mTOR). PML physically interacts with mTOR and negatively regulates its association with the small GTPase Rheb by favouring mTOR nuclear accumulation. Notably, Pml-/- cells and tumours display higher sensitivity both in vitro and in vivo to growth inhibition by rapamycin, and lack of PML inversely correlates with phosphorylation of ribosomal protein S6 and tumour angiogenesis in mouse and human tumours. Thus, our findings identify PML as a novel suppressor of mTOR and neoangiogenesis.
Subject(s)
Hypoxia-Inducible Factor 1, alpha Subunit/biosynthesis , Neoplasm Proteins/metabolism , Neovascularization, Pathologic , Nuclear Proteins/metabolism , Protein Biosynthesis , Protein Kinases/metabolism , Repressor Proteins/metabolism , Transcription Factors/metabolism , Tumor Suppressor Proteins/metabolism , Animals , Cell Hypoxia/physiology , Cell Line, Tumor , Cell Nucleus/metabolism , Fibroblasts , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Ischemia/genetics , Ischemia/metabolism , Mice , Monomeric GTP-Binding Proteins/metabolism , Neoplasm Proteins/deficiency , Neoplasm Proteins/genetics , Neoplasms/blood supply , Neoplasms/genetics , Neoplasms/metabolism , Neuropeptides/metabolism , Nuclear Proteins/deficiency , Nuclear Proteins/genetics , Phosphorylation , Promyelocytic Leukemia Protein , Protein Binding , Ras Homolog Enriched in Brain Protein , Ribosomal Protein S6/metabolism , Sirolimus/pharmacology , TOR Serine-Threonine Kinases , Transcription Factors/deficiency , Transcription Factors/genetics , Tumor Suppressor Proteins/deficiency , Tumor Suppressor Proteins/geneticsABSTRACT
NPM1 is a crucial gene to consider in the context of the genetics and biology of cancer. NPM1 is frequently overexpressed, mutated, rearranged and deleted in human cancer. Traditionally regarded as a tumour marker and a putative proto-oncogene, it has now also been attributed with tumour-suppressor functions. Therefore, NPM can contribute to oncogenesis through many mechanisms. The aim of this review is to analyse the role of NPM in cancer, and examine how deregulated NPM activity (either gain or loss of function) can contribute to tumorigenesis.
Subject(s)
Neoplasms/genetics , Nuclear Proteins , Animals , Cell Transformation, Neoplastic/genetics , Humans , Mutation , Nuclear Proteins/chemistry , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Nucleophosmin , Proto-Oncogene MasABSTRACT
Nucleophosmin (also known as NPM, B23, NO38) is a nucleolar protein directly implicated in cancer pathogenesis, as the NPM1 gene is found mutated and rearranged in a number of haematological disorders. Furthermore, the region of chromosome 5 to which NPM1 maps is deleted in a proportion of de novo human myelodysplastic syndromes (MDS), and loss of chromosome 5 is extremely frequent in therapy-related MDS. NPM is a multifunctional protein, and its role in oncogenesis is controversial as NPM has been attributed with both oncogenic and tumour suppressive functions. To study the function of Npm in vivo, we generated a hypomorphic Npm1 mutant series (Npm1+/- < Npm1(hy/hy) < Npm1-/-) in mouse. Here we report that Npm is essential for embryonic development and the maintenance of genomic stability. Npm1-/- and Npm1(hy/hy) mutants have aberrant organogenesis and die between embryonic day E11.5 and E16.5 owing to severe anaemia resulting from defects in primitive haematopoiesis. We show that Npm1 inactivation leads to unrestricted centrosome duplication and genomic instability. We demonstrate that Npm is haploinsufficient in the control of genetic stability and that Npm1 heterozygosity accelerates oncogenesis both in vitro and in vivo. Notably, Npm1+/- mice develop a haematological syndrome with features of human MDS. Our findings uncover an essential developmental role for Npm and implicate its functional loss in tumorigenesis and MDS pathogenesis.
Subject(s)
Cell Transformation, Neoplastic , Embryonic Development , Neoplasms/metabolism , Neoplasms/pathology , Nuclear Proteins/metabolism , Animals , Apoptosis/genetics , Cell Cycle/genetics , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , Cells, Cultured , Centrosome/metabolism , Embryo Loss/genetics , Fibroblasts , Gene Deletion , Genomic Instability/genetics , Hematopoiesis/genetics , In Situ Hybridization, Fluorescence , Mice , Mice, Knockout , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/pathology , Neoplasms/genetics , Nuclear Proteins/deficiency , Nuclear Proteins/genetics , NucleophosminABSTRACT
Mutations in DKC1 cause dyskeratosis congenita (DC), a disease characterized by premature aging and increased tumor susceptibility. The DKC1 protein binds to the box H + ACA small nucleolar RNAs and the RNA component of telomerase. Here we show that hypomorphic Dkc1 mutant (Dkc1m) mice recapitulate in the first and second generations (G1 and G2) the clinical features of DC. Dkc1m cells from G1 and G2 mice were impaired in ribosomal RNA pseudouridylation before the onset of disease. Reductions of telomere length in Dkc1m mice became evident only in later generations. These results suggest that deregulated ribosome function is important in the initiation of DC, whereas telomere shortening may modify and/or exacerbate DC.
Subject(s)
Cell Cycle Proteins/genetics , Cell Cycle Proteins/physiology , Dyskeratosis Congenita/genetics , Dyskeratosis Congenita/metabolism , Neoplasms/etiology , Nuclear Proteins/genetics , Nuclear Proteins/physiology , Pseudouridine/metabolism , RNA, Ribosomal/metabolism , Anemia , Animals , Apoptosis , Bone Marrow Cells , Colony-Forming Units Assay , Disease Models, Animal , Dyskeratosis Congenita/complications , Female , Genetic Predisposition to Disease , Hematopoietic Stem Cells/physiology , In Situ Hybridization, Fluorescence , Male , Mice , Mutation , Ribosomes/physiology , Telomerase/metabolism , Telomere/metabolism , Telomere/ultrastructureABSTRACT
Modelling human disease in the mouse has become an essential activity in biomedical research in order to unravel molecular mechanisms underlying pathological conditions as well as to determine in vivo the consequences of aberrant gene function. The mouse is by far the most accessible mammalian system physiologically similar to humans. Furthermore, the development of novel techniques for manipulating the murine genome, which allow the in vivo modification of virtually any genomic region in a time and/or tissue specific manner, renders the mouse an ideal model system to study human pathological conditions. Modelling human diseases in mice has reached an even greater relevance in the field of haematological malignancies, due to the already advanced characterization of the molecular basis of many haematological disorders. In this review, we describe the most important technological developments that made it possible to reproduce in the mouse the genetic lesions that characterize human haematological malignancies, thus often generating faithful mouse models of the human condition. We provide specific examples of the advantages and limitations of the various genetic approaches utilized to model leukaemia and lymphoma in the mouse. Finally, we discuss the power of mouse modelling in developing and testing novel therapeutic modalities in pre-clinical studies.